Pomalidomide
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Pomalidomide
- Generic name
- POMALIDOMIDE
- Manufacturer
- Cipla USA Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- a0c16478-1a0c-4be0-be75-cb9e4543d71a
- SPL ID
- d7629b96-2ace-4a2e-a70c-e73d41a990f9
- Version
- 1
- Effective date
- 2026-08-13
- Source export date
- 2026-11-13
- Source partition
- 2
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/3b4204ed830f35b16ab24b2123672d7d93066eb0fd8af1cf09b223d0e4568221/drug-label-0002-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:32:16
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 219718 | derived:openfda.application_number |
| application number | ANDA219718 | openfda.application_number | |
| brand name | Pomalidomide | openfda.brand_name | |
| generic name | POMALIDOMIDE | openfda.generic_name | |
| manufacturer name | Cipla USA Inc. | openfda.manufacturer_name | |
| ndc | package | 69097-037-07 | openfda.package_ndc |
| ndc | package | 69097-038-81 | openfda.package_ndc |
| ndc | package | 69097-036-81 | openfda.package_ndc |
| ndc | package | 69097-037-81 | openfda.package_ndc |
| ndc | package | 69097-039-07 | openfda.package_ndc |
| ndc | package | 69097-039-81 | openfda.package_ndc |
| ndc | package | 69097-038-07 | openfda.package_ndc |
| ndc | package | 69097-036-07 | openfda.package_ndc |
| ndc | product | 69097-039 | openfda.product_ndc |
| ndc | product | 69097-036 | openfda.product_ndc |
| ndc | product | 69097-037 | openfda.product_ndc |
| ndc | product | 69097-038 | openfda.product_ndc |
| ndc11 | package | 69097003981 | derived:openfda.package_ndc |
| ndc11 | package | 69097003607 | derived:openfda.package_ndc |
| ndc11 | package | 69097003881 | derived:openfda.package_ndc |
| ndc11 | package | 69097003707 | derived:openfda.package_ndc |
| ndc11 | package | 69097003907 | derived:openfda.package_ndc |
| ndc11 | package | 69097003681 | derived:openfda.package_ndc |
| ndc11 | package | 69097003807 | derived:openfda.package_ndc |
| ndc11 | package | 69097003781 | derived:openfda.package_ndc |
| rxcui | 1369734 | openfda.rxcui | |
| rxcui | 1369730 | openfda.rxcui | |
| rxcui | 1369726 | openfda.rxcui | |
| rxcui | 1369718 | openfda.rxcui | |
| spl id | d7629b96-2ace-4a2e-a70c-e73d41a990f9 | id | |
| spl set id | a0c16478-1a0c-4be0-be75-cb9e4543d71a | set_id | |
| unii | D2UX06XLB5 | openfda.unii |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM Embryo-Fetal Toxicity Pomalidomide capsule is contraindicated in pregnancy. Pomalidomide is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting pomalidomide capsule treatment. Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after stopping pomalidomide capsule treatment [see Contraindications (4) , Warnings and Precautions (5.1) and Use in Specific Populations (8.1 , 8.3 )]. Pomalidomide capsule is only available through a restricted distribution program called PS-Pomalidomide REMS [see Warnings and Precautions ( 5.2 )]. Information about PS-Pomalidomide REMS program is available at www.pomalidomideREMS.com or by calling the REMS Call Center at 1-888-423-5436. Venous and Arterial Thromboembolism Deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke occur in patients with multiple myeloma treated with pomalidomide capsules. Prophylactic antithrombotic measures were employed in clinical trials. Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment of the patient's underlying risk factors [see Warnings and Precautions ( 5.3 )]. WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM See full prescribing information for complete boxed warning EMBRYO-FETAL TOXICITY Pomalidomide capsule is contraindicated in pregnancy. Pomalidomide is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe life-threatening birth defects ( 4 , 5.1 , 8.1 ). For females of reproductive potential: Exclude pregnancy before start of treatment. Prevent pregnancy during treatment by the use of 2 reliable methods of contraception ( 5.1 , 8.3 ). Pomalidomide capsule is available only through a restricted program called PS- Pomalidomide REMS ( 5.2 ). VENOUS AND ARTERIAL THROMBOEMBOLISM Deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke occur in patients with multiple myeloma treated with pomalidomide capsules. Antithrombotic prophylaxis is recommended ( 5.3 ).
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS • Increased Mortality: Observed in patients with MM when pembrolizumab was added to dexamethasone and a thalidomide analogue (5.4). • Hematologic Toxicity: Neutropenia was the most frequently reported Grade 3/4 adverse event. Monitor patients for hematologic toxicities, especially neutropenia (5.5). • Hepatotoxicity: Hepatic failure including fatalities; monitor liver function tests monthly (5.6). • Severe Cutaneous Reactions: Discontinue pomalidomide capsules for severe reactions (5.7). • Tumor Lysis Syndrome (TLS): Monitor patients at risk of TLS (i.e., those with high tumor burden) and take appropriate precautions (5.11). • Hypersensitivity: Monitor patients for potential hypersensitivity. Discontinue pomalidomide capsules for angioedema and anaphylaxis (5.12). 5.1 Embryo-Fetal Toxicity Pomalidomide is a thalidomide analogue and is contraindicated for use during pregnancy. Thalidomide is a known human teratogen that causes severe birth defects or embryo-fetal death [see Use in Specific Populations ( 8.1 )] . Pomalidomide capsule is only available through PS- Pomalidomide REMS [see Warnings and Precautions ( 5.2 )]. Females of Reproductive Potential Females of reproductive potential must avoid pregnancy for at least 4 weeks before beginning pomalidomide capsule therapy, during therapy, during dose interruptions and for at least 4 weeks after completing therapy. Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with pomalidomide capsules, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of pomalidomide capsule therapy. Two negative pregnancy tests must be obtained prior to initiating therapy. The first test should be performed within 10-14 days and the second test within 24 hours prior to prescribing pomalidomide capsule therapy and then weekly during the first month, then monthly thereafter in females with regular menstrual cycles, or every 2 weeks in females with irregular menstrual cycles [see Use in Specific Populations ( 8.3 )]. Males Pomalidomide is present in the semen of patients receiving the drug. Therefore, males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking pomalidomide capsules and for up to 4 weeks after discontinuing pomalidomide capsules, even if they have undergone a successful vasectomy. Male patients taking pomalidomide capsules must not donate sperm [see Use in Specific Populations ( 8.3 )] . Blood Donation Patients must not donate blood during treatment with pomalidomide capsules and for 4 weeks following discontinuation of the drug because the blood might be given to a pregnant female patient whose fetus must not be exposed to pomalidomide. 5.2 PS-Pomalidomide REMS Because of the embryo-fetal risk [see Warnings and Precautions ( 5.1 )], pomalidomide capsule is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS), “ PS-P omalidomide REMS” . Required components of PS- Pomalidomide REMS include the following: Prescribers must be certified with PS- Pomalidomide REMS by enrolling and complying with the REMS requirements. Patients must sign a Patient-Physician Agreement Form and comply with the REMS requirements. In particular, female patients of reproductive potential who are not pregnant must comply with the pregnancy testing and contraception requirements [see Use in Specific Populations ( 8.3 )] and males must comply with contraception requirements [see Use in Specific Populations ( 8.3 )]. Pharmacies must be certified with PS-P omalidomide REMS , must only dispense to patients who are authorized to receive pomalidomide capsules and comply with REMS requirements. Further information about PS- Pomalidomide REMS is available at www.PS-PomalidomideREMS.com or by telephone at 1-888-423-5436. 5.3 Venous and Arterial Thromboembolism Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboembolic events (myocardial infarction and stroke) have been observed in patients treated with pomalidomide. In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with pomalidomide and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. Venous thromboembolic events (VTE) occurred in 4.7% of patients treated with pomalidomide and Low-dose Dex, and 1.3% of patients treated with high-dose dexamethasone. Arterial thromboembolic events include terms for arterial thromboembolic events, ischemic cerebrovascular conditions, and ischemic heart disease. Arterial thromboembolic events occurred in 3.0% of patients treated with pomalidomide and Low-dose Dex, and 1.3% of patients treated with high-dose dexamethasone. Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment of the patient's underlying risk factors. 5.4 Increased Mortality in Patients with Multiple Myeloma When Pembrolizumab Is Added to a Thalidomide Analogue and Dexamethasone In two randomized clinical trials in patients with MM, the addition of pembrolizumab to a thalidomide analogue plus dexamethasone, a use for which no PD-1 or PD-L1 blocking antibody is indicated, resulted in increased mortality. Treatment of patients with MM with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials. 5.5 Hematologic Toxicity Multiple Myeloma In trials 1 and 2 in patients who received pomalidomide + Low-dose Dex, neutropenia was the most frequently reported Grade 3 or 4 adverse reaction, followed by anemia and thrombocytopenia. Neutropenia of any grade was reported in 51% of patients in both trials. The rate of Grade 3 or 4 neutropenia was 46%. The rate of febrile neutropenia was 8%. Monitor patients for hematologic toxicities, especially neutropenia. Monitor complete blood counts weekly for the first 8 weeks and monthly thereafter. Patients may require dose interruption and/or modification [see Dosage and Administration ( 2.4 )] . Kaposi Sarcoma In Trial 12-C-0047, hematologic toxicities were the most common (all grades and Grade 3 or 4) adverse reactions [see Adverse Reactions (6.1)] . Fifty percent of patients had Grade 3 or 4 neutropenia. Monitor patients for hematologic toxicities, especially decreased neutrophils. Monitor complete blood counts every 2 weeks for the first 12 weeks and monthly thereafter. Withhold, reduce the dose, or permanently discontinue pomalidomide capsules based on the severity of the reaction [see Dosage and Administration (2.4)] . 5.6 Hepatotoxicity Hepatic failure, including fatal cases, has occurred in patients treated with pomalidomide. Elevated levels of alanine aminotransferase and bilirubin have also been observed in patients treated with pomalidomide. Monitor liver function tests monthly. Stop pomalidomide capsules upon elevation of liver enzymes and evaluate. After return to baseline values, treatment at a lower dose may be considered. 5.7 Severe Cutaneous Reactions Severe cutaneous reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. DRESS may present with a cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, and/or lymphadenopathy with systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and/or pericarditis. These reactions can be fatal. Consider pomalidomide capsules interruption or discontinuation for Grade 2 or 3 skin rash. Permanently discontinue pomalidomide capsules for Grade 4 rash, exfoliative or bullous rash, or for other severe cutaneous reactions such as SJS, TEN or DRESS [see Dosage and Administration ( 2.5 )] . 5.8 Dizziness and Confusional State In trials 1 and 2 in patients who received pomalidomide + Low-dose Dex, 14% of patients experienced dizziness and 7% of patients experienced a confusional state; 1% of patients experienced Grade 3 or 4 dizziness, and 3% of patients experienced Grade 3 or 4 confusional state. Instruct patients to avoid situations where dizziness or confusional state may be a problem and not to take other medications that may cause dizziness or confusional state without adequate medical advice. 5.9 Neuropathy In trials 1 and 2 in patients who received pomalidomide + Low-dose Dex, 18% of patients experienced neuropathy, with approximately 12% of the patients experiencing peripheral neuropathy. Two percent of patients experienced Grade 3 neuropathy in trial 2. There were no cases of Grade 4 neuropathy adverse reactions reported in either trial. 5.10 Risk of Second Primary Malignancies Cases of acute myelogenous leukemia have been reported in patients receiving pomalidomide as an investigational therapy outside of MM. 5.11 Tumor Lysis Syndrome Tumor lysis syndrome (TLS) may occur in patients treated with pomalidomide. Patients at risk for TLS are those with high tumor burden prior to treatment. These patients should be monitored closely and appropriate precautions taken. 5.12 Hypersensitivity Hypersensitivity, including angioedema, anaphylaxis, and anaphylactic reactions to pomalidomide have been reported. Permanently discontinue pomalidomide capsules for angioedema or anaphylaxis [see Dosage and Administration ( 2.5 )] .
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions table
<table width="100%"><caption>Table 6: Frequency of Select Laboratory Abnormalities (≥ 10 %) Worsening from Baseline in Patients Who Received Pomalidomide in Trial 12-C-0047</caption><col width="34%" align="left" valign="middle"/><col width="33%" align="left" valign="middle"/><col width="33%" align="left" valign="middle"/><thead><tr><th styleCode="Botrule Lrule Rrule Toprule" align="center"><content styleCode="bold">Laboratory Abnormality</content></th><th styleCode="Botrule Rrule Toprule" align="center"><content styleCode="bold">Grades 1-4*</content><content styleCode="bold">%</content></th><th styleCode="Botrule Rrule Toprule" align="center"><content styleCode="bold">Grades 3-4*</content><content styleCode="bold">%</content></th></tr></thead><tbody><tr><td colspan="3" styleCode="Botrule Lrule Rrule Toprule" valign="top" align="justify"><paragraph><content styleCode="bold">Hematology</content></paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule" valign="top" align="justify"><paragraph>Decreased Absolute Neutrophil Count</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>96</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>50</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule" valign="top" align="justify"><paragraph>Decreased White Blood Cells</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>79</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>3.6</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule" valign="top" align="justify"><paragraph>Decreased Hemoglobin</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>54</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>0</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule" valign="top" align="justify"><paragraph>Decreased Platelets</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>54</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>0</paragraph></td></tr><tr><td colspan="3" styleCode="Botrule Lrule Rrule" valign="top" align="justify"><paragraph>Chemistry</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule" valign="top" align="justify"><paragraph>Elevated Creatinine</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>86</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>3.6</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule" valign="top" align="justify"><paragraph>Elevated Glucose</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>57</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>7</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule" valign="top" align="justify"><paragraph>Decreased Albumin</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>54</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>0</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule" valign="top" align="justify"><paragraph>Decreased Phosphate</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>54</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>25</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule" valign="top" align="justify"><paragraph>Decreased Calcium</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>50</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>0</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule" valign="top" align="justify"><paragraph>Increased Alanine Aminotransferase (ALT)</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>32</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>0</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule" valign="top" align="justify"><paragraph>Increased Aspartate Aminotransferase (AST)</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>25</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>0</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule" valign="top" align="justify"><paragraph>Elevated Creatinine Kinase</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>25</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>7</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule" valign="top" align="justify"><paragraph>Decreased Magnesium</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>14</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>0</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule" valign="top" align="justify"><paragraph>Elevated Alkaline Phosphate</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>14</paragraph></td><td styleCode="Botrule Rrule" valign="top" align="center"><paragraph>3.6</paragraph></td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.